3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
143
Neoplasm Metastasis
16
Ovarian Neoplasms
6
Advanced Breast Cancer
6
Prostatic Neoplasms
5
Breast Cancer Metastatic
5
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Lobular
3
Lung Neoplasms
2
HER2-positive Breast Cancer
2
Exanthema
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms, Male
2
Triple Negative Breast Neoplasms
1
The Neoadjuvant Therapy
1
Stomach Neoplasms
1
Solid Tumor
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Sarcoma
1
Salivary Gland Neoplasms
1
Patient Acceptance of Health Care
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Malignant Neoplasms of Female Genital Organs
1
Interventions
Loperamide
4
Irinotecan
4
Probiotics
3
Fecal Microbiota Transplantation
3
Octreotide
2
Leucovorin
2
Fluorouracil
2
Calcium Aluminosilicate
2
telotristat ethyl
1
shosaiko-to
1
maltodextrin
1
ceterizine hydrochloride
1
capivasertib
1
cabazitaxel
1
bile acid binding proteins
1
XRP6258
1
Theophylline
1
Temozolomide
1
Surveys and Questionnaires
1
Sulfasalazine
1
Sugars
1
Standard of Care
1
Raloxifene Hydrochloride
1
Radiation
1
Prednisone
1
Oxaliplatin
1
Long-Term Synaptic Depression
1
Injections
1
Granulocyte Colony-Stimulating Factor
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Diarrhea
×
Fulvestrant
×
Clear all
NCT07426822
2026-02-24
SAFE-CAP
Yale University
Phase 2
Not yet recruiting
108 enrolled